Table 4.
Occurrence of AEs with different treatment modalities
| Variable | Cetuximab + capecitabine (n = 18) | Capecitabine (n = 21) | p value (overall) | p value (grade ≥3) | ||
|---|---|---|---|---|---|---|
| grade <3, n (%) | grade ≥3, n (%) | grade <3, n (%) | grade ≥3, n (%) | |||
| Neutropenia | 2 (11.1) | 1 (5.6) | 3 (14.3) | 1 (4.8) | 1.00 | 1.00 |
| Thrombocytopenia | 1 (5.6) | 0 (0) | 1 (4.8) | 0 (0) | 1.00 | 1.00 |
| Anemia | 1 (5.6) | 0 (0) | 1 (4.8) | 0 (0) | 1.00 | 1.00 |
| Diarrhea | 7 (38.9) | 2 (11.1) | 4 (20.0) | 0 (0) | 0.09 | 0.21 |
| Nausea or vomiting | 2 (11.1) | 0 (0) | 3 (14.3) | 0 (0) | 1.00 | 1.00 |
| Hepatotoxicity | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) | 0.46 | 1.00 |
| Rash acneiform | 7 (38.9) | 3 (16.7) | 2 (9.5) | 0 (0) | 0.04 | 0.09 |
| Fatigue | 4 (22.2) | 0 (0) | 3 (14.3) | 1 (4.8) | 1.00 | 1.00 |
| Hand-foot syndrome | 9 (50.0) | 2 (11.1) | 10 (47.6) | 3 (14.3) | 1.00 | 1.00 |
| Mucositis | 2 (11.1) | 1 (5.6) | 3 (14.3) | 1 (4.8) | 1.00 | 1.00 |